8 
As an additional item on the agenda. Dr. Fredrickson asked that 
the regulatory agencies, OSHA, CDC, FDA, EPA, provide an analysis 
of their authorities and roles in undertaking functions required 
in the regulation of recombinant DNA research. In the ensuing 
Committee discussion, it was suggested that perhaps the General 
Counsels of each of the Agencies should meet before the next 
meeting to reach a consensus on regulatory authorities. It was 
alternately suggested that each regulatory agency coordinate with 
a research agency to which it is most closely related. A final 
suggestion, which was the one adopted, was the Counsel of each 
regulatory Agency review that Agency's authority and provide an 
analysis that will be presented at the next meeting of the 
Interagency Committee. Dr. Kennedy, from the Office of Science and 
Technology Policy, noted that the enforcement of the provisions of 
the NIH guidelines would depend on the development of detection 
systems and he recommended that the Committee review this matter 
at a future meeting. 
In conclusion, it was agreed that at the next meeting which should 
be held within three weeks, two items on the agenda would be a 
review of the respective roles and responsibilities of the research 
agencies and the regulatory agencies in the conduct and regulation 
of recombinant DNA research. Other items for the agenda could be 
suggested by other representatives. Dr. Fredrickson recommended and 
the Committee approved the creation of a subcommittee to develop 
future agendas and Issues for review. 
Respectfully submitted. 
Joseph C. Perpich, M.D., J.D. 
Associate Director for 
Program Planning and Evaluation 
National Institutes of Health 
Bethesda, Maryland 20014 
November 9, 1976 
f 175] 
